Research Article
Synchronous and Metachronous Breast Malignancies: A Cross-Sectional Retrospective Study and Review of the Literature
Table 3
Other characteristics of the tumors: in this table we present prevalences and
values referring to chi-square test.
| | | UBC | 1st MBC | 2nd MBC | 1st SBC | 2nd SBC | |
| | Grading | | | | | | | | G1 | 7.16% (35/489) | 7.69% (3/39) | 7.5% (3/40) | 12.5% (2/16) | 18.75% (3/16) | 0.480 | | G2 | 67.48% (330/489) | 41.03% (16/39) | 55% (22/40) | 81.25% (13/16) | 68.75% (11/16) | <0.05 | | G3 | 25.36% (124/489) | 51.28% (20/39) | 37.5% (15/40) | 6.25% (1/16) | 12.5% (2/16) | <0.05 | | ER positivity | 73.3% (387/528) | 51.28% (20/39) | 67.5% (27/40) | 75% (12/16) | 81.25% (13/16) | <0.05 | | PR positivity | 68.94% (364/528) | 43.59% (17/39) | 60% (24/40) | 75% (12/16) | 75% (12/16) | <0.05 | | HER-2/Neu positivity | 8.9% (47/528) | 7.69% (3/39) | 12.5% (5/40) | 6.25% (1/16) | 6.25% (1/16) | 0.912 | | Mib-1/Ki-67 (%) | | | | | | | | 1 to 20 | 34.98% (85/243) | 57.14% (4/7) | 32% (8/25) | 57.14% (4/7) | 60% (3/5) | 0.376 | | 20 to 30 | 18.11% (44/243) | 0% (0/7) | 12% (3/25) | 0% (0/7) | 0% (0/5) | 0.331 | | >30 | 46.91% (114/243) | 42.86% (3/7) | 56% (14/25) | 42.86% (3/7) | 40% (2/5) | 0.911 | | Multifocality | 26.7% (141/528) | 5.13% (2/39) | 27.5% (11/40) | 50% (8/16) | 18.75% (3/16) | <0.05 | | Extended in situ component | 22.16% (117/528) | 17.95% (7/39) | 32.5% (13/40) | 25% (4/16) | 0% (0/16) | 0.110 | | Peritumoral vascular invasion | 6.82% (36/528) | 5.13% (2/39) | 7.5% (3/40) | 6.25% (1/16) | 0% (0/16) | 0.850 | | Comedo-like necrosis | 8.9% (47/528) | 2.56% (1/39) | 12.5% (5/40) | 6.25% (1/16) | 6.25% (1/16) | 0.581 | | Lymph node isolated tumor cells | 3.6% (19/528) | 0% (0/39) | 0% (0/40) | 0% (0/16) | 0% (0/16) | 0.390 | | Lymph node extracapsular invasion | 2.27% (12/528) | 0% (0/39) | 0% (0/40) | 12.5% (2/16) | 0% (0/16) | <0.05 |
|
|
